-
-
Call more information
660-596-2224 -
Author: Jonathan B. Cohen, MD, MS Anesthesia Patient Safety Foundation Oct 2023 In March of this year, the U.S. Food and Drug Administration (FDA) approved naloxone hydrochloride nasal spray for over-the-counter, nonprescription use. This move was consistent with longstanding recommendations by the American Society of Anesthesiologists (ASA) and testimony given before several of its committees […]
Read MoreAuthors: John Beard, MD et al Anesthesia Patient Safety Foundation Oct 2023 Nonoperating room anesthesia (NORA) cases are projected to exceed 50% of total anesthesia cases in the near future.1 Although one large-scale study failed to show a difference in mortality between NORA and operating room (OR) settings,2 multiple analyses of data from the American Society of […]
Read MoreAuthors: Candace Chang, MD, MPH et al Anesthesia Patient Safety Foundation Oct 2023 INTRODUCTION While patient safety is an established field of study, little attention has been directed to clinician safety. According to the Occupational Health Safety Network, 1 in 5 nonfatal occupational injuries occurs in the health care and social assistance industry, and health […]
Read MoreAuthors: Gabor Erdoes, M.D., Ph.D. et al Anesthesiology September 2023. To the Editor: Nadtochiy et al. report using intravenous dabigatran, a direct thrombin inhibitor (DTI), for anticoagulation in an animal model of simulated cardiopulmonary bypass (CPB). Activated clotting time, thromboelastometric reaction time, and fibrin deposition in sections of the arterial line filters were analyzed to compare anticoagulation with […]
Read MoreAuthors: Michael P. Eaton, M.D., F.A.S.A. et al Anesthesiology September 2023. In Reply: The authors thank Drs. Erdoes, Koster, and Levy for their very cogent and detailed analysis of our study. We agree with many of the points they made, specifically the very limited effect dabigatran has on coagulation due to its specificity for thrombin. Most would […]
Read More